Why Duodopa?

Reassure patients that it’s the same levodopa,
with a change in delivery that leads to:

Unlocking smooth drug delivery

Duodopa: Provides a smooth, consistent, adjustable delivery of levodopa (plus carbidopa) directly into the jejunum or duodenum via a PEG/J tube1

  • Disrupted transit of levodopa is a common feature of Parkinson's disease and can make control unpredictable. Duodopa has a way round it1,6
  • For eligible patients where the levodopa works but the delivery doesn't, Duodopa can unlock disease control1,2

An open-label study shows consistent levodopa levels during the infusion1,5

Adapted from Nyholm D et al. 2013.more info

Duodopa rapidly achieves consistent plasma levels of levodopa (within a few hours) over the course of the infusion1,5

Helping unlock long-term benefit

An open-label study shows Duodopa significantly
improves motor symptoms at 54 weeks2

Adapted from Fernandez HH et al. 2015. Significant improvements in 'off' time and corresponding 'on' time without dyskinesia (baseline to 54 weeks).more info

In an open-label study Duodopa offered clinically
meaningful improvements in motor function vs. baseline2

Adapted from Fernandez HH et al. 2015.
TD: Troublesome dyskinesia.
more info

In this study, patients receiving the levodopa-carbidopa intestinal gel experienced significant improvements in functioning as early as 4 weeks after beginning therapy, which was maintained throughout the study2

Unlocking reassurance with long-term tolerability

An open-label study shows Duodopa offers a well understood adverse event profile2

Adapted from Fernandez HH et al. 2015.
NJ: Nasojejunal.
more info

For the majority of patients AEs were mild (19%) or moderate (44%) and transient2

Low withdrawal rate (8%) due to AEs, most commonly due to complication of insertion device2

Unlocking a reduced burden of care for caregivers4

In an open-label study caregivers indicated improvements in the burden of care when caring for patients on Duodopa therapy (n=7)4

Adapted from Santos-Garcia et al. 2012.

Caregivers indicate improvements in the strain they experience when caring for patients on Duodopa therapy (n=7)4

Adapted from Santos-Garcia et al. 2012. Open-label study of seven patients with advanced PD treated with Duodopa. All patients had motor fluctuations and dyskinesia prior to Duodopa. Mean follow up with Duodopa therapy 31.4 ±7.9 months.